Business Wire

Thales Brings Passwordless Fingerprint Authentication to the Enterprise

18.10.2023 10:00:00 EEST | Business Wire | Press release

Share

Thales , the leading global technology and security provider, today announced the SafeNet IDPrime FIDO Bio Smart Card, a security key that enables strong multi-factor authentication (MFA) for the enterprise. This new contactless smart card allows users to quickly and securely access enterprise devices, applications, and cloud services using a fingerprint instead of a password.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231018403020/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

According to the 2023 Verizon Data Breach Investigations Report, the three primary ways in which attackers access an organization are stolen credentials, phishing and exploitation of vulnerabilities. In fact, 49% of all breaches involved stolen credentials. With these threats top of mind for organizations moving to the cloud, many are grappling with low user adoption of MFA, which is often cited as cumbersome.

The SafeNet IDPrime FIDO Bio Smart Card facilitates end user adoption of passwordless MFA, allowing users to easily enroll and authenticate using biometrics. Instead of using a password, users can access with a fingerprint, using the on-card sensor. The smart cards also support contactless capabilities, which allows users to simply tap the card on any device supporting NFC. For enterprise users, this smart card provides multiple benefits including better speed, security, and convenience than traditional passwords.

Using these security keys, users can be assured of strong protection against account takeover and phishing on enterprise devices. User biometrics are securely stored in the card’s chip and never leave the smart card itself, ensuring a strong level of data privacy. This solution can be used for all digital resources supporting the FIDO2 standard, including Windows, Mac, Linux and more.

Thales is a market leader in biometrics, proving success with contactless biometric payment cards in highly regulated sectors. The addition of the SafeNet IDPrime FIDO Bio Smart Card further enriches its existing portfolio of FIDO security keys, now providing enterprise customers with the same secure biometric capabilities.

Danny de Vreeze, Vice President, Identity and Access Management Products at Thales: “ The human factor continues to be a challenging pain point in the modern enterprise, with shifts to remote work and the cloud expanding many organizations’ attack surfaces. MFA adoption has been a common barrier to ensuring security, as many users find it cumbersome and choose to bypass it. The SafeNet IDPrime FIDO Bio Smart Card helps to solve this challenge, introducing a physical form factor to strengthen security, while also providing a user experience that is both quick and seamless. Adding to a strong portfolio of FIDO-supported security keys and solutions, this product is on the cutting edge of phishing-resistant authentication.”

The Thales SafeNet IDPrime FIDO Bio Smart Card is available today. More information is available here.

About Thales

 

Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.

 

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

 

Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.

PLEASE VISIT

Thales Group

Cloud Protection & Licensing Solutions | Thales Group

Cybersecurity Solutions | Thales Group

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS
Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0)6 60 38 48 92
marion.bonnet@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye